Study Tracks Severe Alcohol Hepatitis Outcomes
A real-world analysis of 1,630 U.S. adults hospitalized with severe alcohol-associated hepatitis reports survival, rehospitalization and transplant estimates.
Updated on Nov. 6, 2026 in Substance Abuse
Bausch Health's Salix Pharmaceuticals presented a research poster on severe alcohol-associated hepatitis at The Liver Meeting 2026 in Denver, Colorado. The study estimates 62.0% overall survival at 12 months among the 1,630 adults evaluated.
Why it matters
The figures offer a real-world view of how patients with severe alcohol-associated hepatitis fare after hospitalization, including how often they return to the hospital and how often they reach liver transplantation.
The figures come from a real-world cohort of 1,630 hospitalized U.S. adults, with 62.0% estimated survival at 12 months and 8.5% estimated transplantation at 12 months. Rehospitalization reached 31.4% within 30 days of discharge and an estimated 69.1% by 12 months, while the drivers of these outcomes were not reported.
The players
Salix Pharmaceuticals
A pharmaceutical company and subsidiary of Bausch Health that develops gastrointestinal and liver-focused therapies.
The details
Salix Pharmaceuticals, a Bausch Health business, presented the analysis as a research poster at The Liver Meeting 2026 in Denver, Colorado, held November 5-9. The study analyzed a large real-world cohort of hospitalized patients with severe alcohol-associated hepatitis, a serious inflammatory condition of the liver linked to heavy alcohol use.
Timeline
November 5-9, 2026: The Liver Meeting 2026 is held in Denver, Colorado, where the poster is presented.
November 6, 2026: Salix Pharmaceuticals issues a press release announcing the research poster.
30 days after discharge: The window in which 31.4% of patients were rehospitalized.
Health Landscape
The analysis reflects the research presented each year at The Liver Meeting, the American Association for the Study of Liver Diseases' annual forum for liver disease data. Real-world cohort figures like these add population-level evidence on outcomes for severe alcohol-associated hepatitis beyond controlled trial settings.
Patients hospitalized for severe alcohol-associated hepatitis face substantial risk of returning to the hospital, with an estimated 69.1% rehospitalized by 12 months. Families and clinicians tracking follow-up care can use these figures to plan monitoring after discharge.
The takeaway
Hospital discharge marks the start of a high-risk period for patients with severe alcohol-associated hepatitis, so continued follow-up matters. Reducing readmissions and tracking outcomes over the year after discharge can help improve long-term survival.
Further reading
Explore more on Substance Abuse to see how alcohol-related liver disease fits into broader addiction health coverage.
Source note: This article includes information reported by North Bay Nugget.
